Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 101-111

  Rajashekhar, G ^a   Loganath, A ^a   Roy, A C ^a   Mongelli, J M ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Apoptosis; Gestational trophoblastic disease; Immunocytochemistry; Metastasis; NJG

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CELL MEMBRANE; CELL TYPE; CHORIOCARCINOMA; CONFOCAL IMMUNOFLUORESCENCE MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TECHNIQUE;

EID: 0141869077     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00397-4     Document Type: Article

References (60)

1. Rajashekhar G, Loganath A, Roy AC, Mongelli JM. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: Implications in immune privilege. Gynecol Oncol 2003;91:89-100.
2. Shih IeM, Kurman R.J. Molecular basis of gestational trophoblastic diseases. Curr Mol Med. 2:2002;1-12.
3. Teoh E.S., Dawoood M.Y., Ratnam S.S. Epidemiology of hydatiform mole in Singapore. Am J Obstet Gynaecol. 110:1971;415-420.
4. Song HC, Wu PC. Incidence of hydatiform mole in China: a preliminary survey of more than 3 million women. In: Song HC, Wu PC, editors. Studies on trophoblastic diseases in China. Beijing: International Academic; 1988.
5. McMaster M.T., Bass K.E., Fisher S.J. Human trophoblast invasion autocrine control and paracrine modulation . Ann NY Acad Sci. 734:1994;122-131.
6. Baergen R.N. Gestational choriocarcinoma. Gen Diagn Pathol. 143:1997;127-141.
7. Ober W.B., Edgcomb J.H., Price E.B. Jr. The pathology of choriocarcinoma. Ann NY Acad Sci. 172:1971;299-426.
8. Ishizuka N., Tomoda Y. Gestational trophoblastic disease. 1990;Univ. of Nagoya Press, Nagoya. p. 71-96.
9. Bagshawe K.D. Trophoblastic tumors. Coppleson M. Gynecologic oncology. 2nd ed :1992;1013-1046 Churchill Livingstone, Edinburgh.
10. Haanen C., Vermes I. Apoptosis programmed cell death in fetal development . Eur J Obstet Gynecol Reprod Biol. 64:1996;129-133.
11. Walker N.I., Bennett R.E., Kerr J.F. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat. 185:1989;19-32.
12. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor. EMBO J. 14:1995;5579-5588.
13. Ashkenazi A., Dixit V.M. Death receptors signaling and modulation . Science. 281:1998;1309-1312.
14. Leithauser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C., et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 69:1993;415-429.
15. Keane M.M., Ettenberg S.A., Lowrey G.A., Russell E.K., Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56:1996;4791-4798.
16. Butler L.M., Hewett P.J., Butler W.J., Cowled P.A. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer. 77:1998;1454-1459.
17. Ungefroren H., Voss M., Jansen M., Roeder C., Henne-Bruns D., Kremer B., Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 58:1998;1741-1749.
18. Koomagi R., Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer. 84:1999;239-243.
19. Yoong K.F., Afford S.C., Randhawa S., Hubscher S.G., Adams D.H. Fas/Fas ligand interaction in human colorectal hepatic metastases a mechanism of hepatocyte destruction to facilitate local tumor invasion . Am J Pathol. 154:1999;693-703.
20. Mann B., Gratchev A., Bohm C., Hanski M.L., Foss H.D., Demel G., et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer. 79:1999;1262-1269.
21. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
22. Bamberger A., Schulte H., Thuneke I., Erdmann I., Bamberger C.M., Asa S.L. Expression of the apoptosis inducing Fas ligand in human first, and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab. 82:1997;3173-3175.
23. Pawelec G., Heinzel S., Kiessling R., Muller L., Ouyang Q., Zeuthen J. Escape mechanisms in tumor immunity a year 2000 update . Crit Rev Oncog. 11:2000;97-133.
24. Crawford R.A., Newlands E., Rustin G.J., Holden L., A'Hern R., Bagshawe K.D. Gestational trophoblastic disease with liver metastases the Charing Cross experience . Br J Obstet Gynaecol. 104:1997;105-109.
25. Dumur C.I., Koritschoner N.P., Flury A., Panzetta-Dutari G., Bocco J.L., Patrito L.C. Differential expression of a tumor necrosis factor receptor-related transcript in gestational trophoblastic diseases in women. Biol Reprod. 59:1998;621-625.
26. Qiao S., Nagasaka T., Harada T., Nakashima N. p53, Bax and Bcl-2 expression, and apoptosis in gestational trophoblast of complete hydatidiform mole. Placenta. 19:1998;361-369.
27. Mor G., Gutierrez L.S., Eliza M., Kahyaoglu F., Arici A. Fas-fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol. 40:1998;89-94.
28. King A., Thomas L., Bischof P. Cell culture models of trophoblast. II. Trophoblast cell lines - a workshop report. Placenta. 21:(suppl A):2000;S113-119.
29. Patillo R.A., Gey G.O. The establishment of a cell line of human hormone-synthesizing trophoblast cells in vitro. Cancer Res. 28:1968;1231-1236.
30. Nozawa S., Udagawa Y., Sakayori M., Tsukazaki K., Takayama Y., Aoki D., et al. Establishment and characteristics of a new human choriocarcinoma cell line and its production of tumor markers. Nippon Sanka Fujinka Gakkai Zasshi. 39:1987;889-896.
31. Rajashekhar G., Loganath A., Roy A.C., Wong Y.C. Expression and localization of angiogenin in placenta enhanced levels at term over first trimester villi . Mol Reprod Dev. 62:2002;97-101. doi:10.1002/mrd.10116.
32. Blaschitz A., Weiss U., Dohr G., Desoye G. Antibody reaction patterns in first trimester placenta implications for trophoblast isolation and purity screening . Placenta. 21:2000;733-741.
33. Takeuchi Y., Sakakibara R., Ishiguro M. Synthesis and secretion of human chorionic gonadotropin and its subunits in choriocarcinoma cells a comparative study with normal placental cells . Mol Cell Endocrinol. 69:1990;145-156.
34. Xerri L., Devilard E., Hassoun J., Mawas C., Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol. 50:1997;87-91.
35. Wilson S.E., Li Q., Weng J., Barry-Lane P.A., Jester J.V., Liang Q., Wordinger R.J. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci. 37:1996;1582-1592.
36. Hamann K.J., Dorscheid D.R., Ko F.D., Conforti A.E., Sperling A.I., Rabe K.F., White S.R. Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium. Am J Respir Cell Mol Biol. 19:1998;537-542.
37. Liles W.C., Kiener P.A., Ledbetter J.A., Aruffo A., Klebanoff S.J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes implications for the regulation of apoptosis in neutrophils . J Exp Med. 184:1996;429-440.
38. Lynch D.H., Ramsdell F., Alderson M.R. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today. 16:1995;569-574.
39. Yamashita H., Otsuki Y., Matsumoto K., Ueki K., Ueki M. Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle. Mol Hum Reprod. 5:1999;358-364.
40. French L.E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., et al. Fas and Fas ligand in embryos and adult mice ligand expression in several immune-privileged tissues and co-expression in adult tissues characterized by apoptotic cell turnover . J Cell Biol. 133:1996;335-343.
41. Nagata S., Suda T. Fas and Fas ligand lpr and gld mutations . Immunol Today. 16:1995;39-43.
42. Muschen M., Warskulat U., Beckmann M.W. Defining CD95 as a tumor suppressor gene. J Mol Med. 78:2000;312-325.
43. Aggarwal B.B., Singh S., LaPushin R., Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett. 364:1995;5-8.
44. Owen-Schaub L.B., Meterissian S., Ford R.J. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunother. 14:1993;234-241.
45. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med. 6:2000;920-923.
46. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells a mechanism if immune evasion . Nat Med. 2:1996;1361-1366.
47. Muschen M., Moers C., Warskulat U., Niederacher D., Betz B., Even J., et al. CD95 ligand expression in dedifferentiated breast cancer. J Pathol. 189:1999;378-386.
48. Clement M.V., Stamenkovic I. Fas and tumor necrosis factor receptor-mediated cell death similarities and distinctions . J Exp Med. 180:1994;557-567.
49. Owen-Schaub L.B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness . Cancer Res. 54:1994;1580-1586.
50. Owen-Schaub L.B., van Golen K.L., Hill L.L., Price J.E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med. 188:1998;1717-1723.
51. Krueger A., Baumann S., Krammer P.H., Kirchhoff S. FLICE-inhibitory proteins regulators of death receptor-mediated apoptosis . Mol Cell Biol. 21:2001;8247-8254.
52. Budd R.C. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest. 109:2002;437-441.
53. Alderson M.R., Armitage R.J., Maraskovsky E., Tough T.W., Roux E., Schooley K., et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 178:1993;2231-2235.
54. Rathmell J.C., Townsend S.E., Xu J.C., Flavell R.A., Goodnow C.C. Expansion or elimination of B cells in vivo dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor . Cell. 87:1996;319-329.
55. Fidler I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst. 87:1995;1588-1592.
56. Rusciano D., Burger M.M. Why do cancer cells metastasize into particular organs. BioEssays. 14:1992;185-194.
57. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., et al. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
58. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
59. Kataoka T., Schroter M., Hahne M., Schneider P., Irmler M., Thome M., et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol. 161:1998;3936-3942.
60. Runic R., Lockwood C.J., LaChapelle L., Dipasquale B., Demopoulos R.I., Kumar A., Guller S. Apoptosis and Fas expression in human fetal membranes. J Clin Endocrinol Metab. 83:1998;660-666.